Familial Mediterranean fever successfully treated with etanercept

被引:51
作者
Mor, Adam
Pillinger, Michael H.
Kishimoto, Mitsumasa
Abeles, Aryeh M.
Livneh, Avi
机构
[1] NYU, Div Rheumatol, Hosp Joint Dis, Sch Med,Dept Med, New York, NY 10003 USA
[2] Chaim Sheba Med Ctr, Heller Inst Med Res, IL-52621 Tel Hashomer, Israel
[3] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel
关键词
familial Mediterranean fever; tumor necrosis factor; etanercept;
D O I
10.1097/01.rhu.0000255772.25658.7c
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Colchicine is the only drug known to effectively prevent familial Mediterranean fever (FMF) attacks, as well as FMF-associated amyloidosis. Unfortunately, colchicine is neither always effective nor always well tolerated, leaving some patients and their physicians with inadequate weaponry to fight this hazardous disease. We present a patient with recurrent episodes of abdominal, scrotal, and joint attacks, who was diagnosed with FMF and advised to take colchicine. Diarrhea prevented optimal treatment with this drug and led to a trial of etanercept, with resolution of FMF manifestations. This case adds to a growing body of evidence suggesting that tumor necrosis factor (TNF) blockade may result in resolution and prevention of further FMF attacks.
引用
收藏
页码:38 / 40
页数:3
相关论文
共 20 条
[1]   A severe autosomal-dominant periodic inflammatory disorder with renal AA amyloidosis and colchicine resistance associated to the MEFV H478Y variant in a Spanish kindred:: An unusual familial Mediterranean fever phenotype or another MEFV-associated periodic inflammatory disorder? [J].
Aldea, A ;
Campistol, JM ;
Arostegui, JI ;
Rius, J ;
Maso, M ;
Vives, J ;
Yagüe, J .
AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2004, 124A (01) :67-73
[2]   Serum sIL-2r, IL-6, IL-10 and TNF-α level in familial Mediterranean fever patients [J].
Baykal, Y ;
Saglam, K ;
Yilmaz, MI ;
Taslipinar, A ;
Akinci, SB ;
Inal, A .
CLINICAL RHEUMATOLOGY, 2003, 22 (02) :99-101
[3]   The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators [J].
Centola, M ;
Wood, G ;
Frucht, DM ;
Galon, J ;
Aringer, M ;
Farrell, C ;
Kingma, DW ;
Horwitz, ME ;
Mansfield, E ;
Holland, SM ;
O'Shea, JJ ;
Rosenberg, HF ;
Malech, HL ;
Kastner, DL .
BLOOD, 2000, 95 (10) :3223-3231
[4]   Infliximab therapy in a patient with familial Mediterranean fever and chronic hip arthritis [J].
Daysal, S ;
Akcil, G ;
Goker, B ;
Haznedaroglu, S ;
Ercan, N ;
Ozturk, MA .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2005, 53 (01) :146-147
[5]   CYTOKINE ACTIVATION DURING ATTACKS OF THE HYPERIMMUNOGLOBULINEMIA-D AND PERIODIC FEVER SYNDROME [J].
DRENTH, JPH ;
VANDEUREN, M ;
VANDERVENJONGEKRIJG, J ;
SCHALKWIJK, CG ;
VANDERMEER, JWM .
BLOOD, 1995, 85 (12) :3586-3593
[6]  
Gang N, 1999, J RHEUMATOL, V26, P890
[7]  
Kiraz S, 1998, CLIN EXP RHEUMATOL, V16, P721
[8]  
LACHMAN HJ, 2002, CLIN EXP RHEUMATOL, V20, pS71
[9]   Colchicine nonresponsiveness in familial Mediterranean fever: Clinical, genetic, pharmacokinetic, and socioeconomic characterization [J].
Lidar, M ;
Scherrmann, JM ;
Shinar, Y ;
Chetrit, A ;
Niel, E ;
Gershoni-Baruch, R ;
Langevitz, P ;
Livneh, A .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2004, 33 (04) :273-282
[10]  
Lidar M, 2003, J RHEUMATOL, V30, P2620